Biogen's Brisk Business
304071
Biogen releases its third-quarter financial results.
288489
BUENOS AIRES, Argentina  - Monsanto Co. MON.N, a  company that has pioneered the development of bioengineered  crops, is pushing hard to recover millions of dollars in lost  revenue in three South American countries where farmers have  sown its wonder seeds without paying royalties.
572919
Biotech titan Genzyme (Nasdaq: GENZ) has its roots in the treatment of rare genetic diseases and also has a significant presence in the treatment of renal diseases and providing diagnostic testing services.
443190
A conglomerate of Japanese companies hopes to develop biochips.
430619
Genzyme Corp. is expanding its research  into gene therapy, a controversial and cutting-edge approach to  treating disease which most companies avoid.
408401
Carl Icahn attempts a board shakeup at Biogen.
667096
The biotech's new cancer candidate passes phase 1 trials.
60402
Biogen Idec Inc. BIIB.O on Monday  reported a quarterly profit on sales of its multiple sclerosis  and cancer drugs versus a year-ago loss, but said costs will  rise in 2005, trimming earnings growth.
541050
A powerful new strategy promises to speed up the effort to link genes to specific diseases. Can you say 'transcriptome'?
744065
Multi-Media Productions (USA), Inc. announces the appearance of  American Probiotics on World Business Review hosted by General  Alexander Haig.  Eliminating the dependency on chemicals may result in substantial cost  savings and healthier turf for grass and tree growth.
584880
Progenics' marketing application for its lead compound gets accepted for review.
683806
The biotech company reported net income of $833 million, or 71 cents per share, for the latest quarter.
51447
Millionaires' club sets genome target A $10m carrot is being dangled at biotech firms to encourage them to redouble efforts to make genome sequencing available to individuals.â¦
432855
Biogen Idec in Cambridge is rumored to be in talks to buy or merge with Elan Corp. in Ireland, though the later company denies any such conversation is taking place, Bloomberg News is reporting.
665690
The developing biopharmaceutical company announces a share offering.
285697
Looking at drug R&D is the best way to begin assessing biotech companies.
610276
The experiment is part of an explosion in the new field of synthetic biology.